Clinical Scorecard: Investigation of Euphorbia Lathyris L. Seed's Mechanisms in Colorectal Cancer Treatment Through Network Pharmacology and Molecular Docking Approaches

At a Glance

Key Highlights

• Colorectal cancer is the second leading cause of cancer-related deaths globally.
• Current treatments include surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy, each with limitations.
• Euphorbia Lathyris L. Seed shows potential in overcoming drug resistance and enhancing treatment efficacy.
• Network pharmacology is utilized to elucidate the mechanisms of TCM in CRC treatment.
• Research indicates TCM can provide meaningful chemoprevention in CRC patients.

Guideline-Based Recommendations

Diagnosis

• Utilize genetic and biomarker testing to identify CRC subtypes.

Management

• Consider integrating TCM approaches alongside conventional therapies for enhanced outcomes.

Monitoring & Follow-up

• Regular assessment of treatment response and side effects in CRC patients.

Risks

• Be aware of potential toxic side effects and drug resistance associated with conventional therapies.

Patient & Prescribing Data

Patients diagnosed with colorectal cancer, especially those with advanced disease.

Euphorbia Lathyris L. Seed may offer a complementary approach to existing therapies, particularly in managing drug resistance.

Clinical Best Practices

• Incorporate a multidisciplinary approach in CRC management.
• Evaluate the potential of TCM as an adjunct therapy in CRC treatment plans.
• Focus on personalized treatment strategies based on patient-specific factors.

References

• Traditional Chinese Medicine Systems Pharmacology Database
• GeneCards
• Online Mendelian Inheritance in Man
• Therapeutic Target Database